Tulodesvenlafaxine to relieve herpes zoster (shingles) pain
Official title: The Analgesic Efficacy and Safety of Oral Medications (Tulodsesvenlafaxine) in Patients With Herpes Zoster
Run by Beijing Tiantan Hospital · NCT07370389 · Data updated 2026-11-12
This trial tests whether adding tulodesvenlafaxine to standard care can reduce moderate-to-severe shingles pain in adults.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 750 (estimated) |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | December 15, 2025 |
| Main results expected | September 30, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | January 27, 2026 |
| Trial ID | NCT07370389 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged over 18 with a shingles rash that began less than 90 days ago, average pain of at least 4 on a 0–10 NRS, and adequate liver and kidney function who can consent and comply with visits.
✕Probably not a fit
Patients with disseminated or ocular herpes zoster, significant liver or renal impairment, prior tulodesvenlafaxine exposure, or those beyond the 90-day window may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with recent herpes zoster (rash onset under 90 days) and moderate-to-severe pain (NRS ≥4) will receive standard antiviral/analgesic therapy either alone or combined with tulodesvenlafaxine, with liver and kidney function requirements for enrollment. The study compares pain scores and safety outcomes between the two groups over the treatment period. Patients with disseminated or ocular HZ, prior tulodesvenlafaxine use, or known hypersensitivity to the drug are excluded. The approach tests whether increasing central serotonin and norepinephrine availability can provide additional analgesia beyond conventional therapy.
Why it matters
Potential benefit: If successful, adding tulodesvenlafaxine could meaningfully reduce acute shingles pain and potentially lower the risk of longer-term postherpetic neuralgia while maintaining acceptable safety.
How similar studies have gone: Other antidepressants and SNRIs (for example duloxetine and venlafaxine) have shown analgesic effects in neuropathic pain and postherpetic neuralgia, but evidence specifically for acute herpes zoster pain is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Ages more than 18 years; * 2\. Patients with onset of HZ rash less than 90 days; * 3\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain); * 4\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal; * 5\. Estimated glomerular filtration rate of 30 mL/min per 1.73 m2 or higher; * 6\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements. Exclusion Criteria: * 1\. History of taking tulodesvenlafaxine; * 2\. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ; * 3\. History of intolerance or hypersensitivity to any active components or excipient of the tulodesvenlafaxine; * 4\. History of systemic immune diseases, organ transplantation, or cancers; * 5\. Pregnancy or breastfeeding; * 6\. Suffering from acute or chronic pain disorders other than HZ.
Where it's running
-
Beijing Tiantan Hospital, Beijing, Beijing 100070
Beijing, China Recruiting
Study contacts
- Study coordinator: Fang Luo
- Email: 13611326978@163.com
- Phone: 13611326978
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Recombinant Zoster Vaccine with ZFA01 Adjuvant in Adults 40+
A two-part study tests a recombinant herpes zoster vaccine in healthy adults aged 40 and older to see if it boosts immune responses and is safe.
-
How long the live shingles vaccine protects you
This will see if the live attenuated shingles vaccine keeps adults from the original Phase III trial protected against herpes zoster for up to six years after vaccination.
-
Recombinant zoster (Shingrix) to see if it lowers new dementia diagnoses in people 76 and older in Finland.
This trial will test whether the Shingrix shingles vaccine lowers the chance of a new dementia diagnosis in people aged 76 or older who live in Finland.
-
Erector spinae plane block versus transcutaneous radiofrequency for postherpetic neuralgia
This project will see if erector spinae plane block or transcutaneous radiofrequency works better to reduce pain in adults with postherpetic neuralgia.
-
Lyophilized shingles mRNA vaccine safety and immune response
This trial will test a lyophilized mRNA vaccine to see if it is safe and produces immune responses in adults aged 40 years and older.
-
Loxoprofen patch for relieving shingles pain
This will test if adding a loxoprofen sodium patch to standard care reduces pain in adults with shingles.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.